-
Mashup Score: 0
Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC - 6 hour(s) ago
Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: @CoreyLangerMD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm. @PennMedicine @gotoPER #gotoPER #WLC25 #lcsm https://t.co/g7SLTtszkN
-
WATCH: @drshieldsmd discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC. @IUCancerCenter @IUMedSchool @gotoPER #gotoPER #WLC25 #lcsm https://t.co/wBQLpp0qjN